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Introduction: Single-nucleotide polymorphisms (SNPs) in the CRP gene are implicated in the regulation of the
constitutional C-reactive protein (CRP) expression and its response to proinflammatory stimuli. Previous reports
suggest that these effects may have an impact on clinical decision-making tools based on CRP, such as the
Disease Activity Score in 28 joints (DAS28). We aimed to investigate the possible association between seven CRP
SNPs, their haplotypes and the serum levels of CRP, as well as DAS28 scores, in two cohorts of untreated active early
rheumatoid arthritis (RA) patients followed during their initial treatment.
Methods: Overall, 315 patients with RA from two randomized controlled trials (the CIMESTRA and OPERA trials)
who were naïve to disease-modifying antirheumatic drugs and steroids with disease durations less than 6 months
were included. Seven CRP SNPs were investigated: rs11265257, rs1130864, rs1205, rs1800947, rs2808632, rs3093077
and rs876538. The genotype and haplotype associations with CRP and DAS28 levels were evaluated using linear
regression analysis adjusted for age, sex and treatment.
Results: The minor allele of rs1205 C > T was associated with decreased CRP levels at baseline (P = 0.03), with the
TT genotype having a 50% reduction in CRP from 16.7 to 8.4 mg/L (P = 0.005) compared to homozygosity of the
major allele, but no association was observed at year 1 (P = 0.38). The common H2 haplotype, characterized by
the T allele of rs1205, was associated with a 26% reduction in CRP at baseline (P = 0.043), although no effect
was observed at year 1 (P = 0.466). No other SNP or haplotype was associated with CRP at baseline or at year 1
(P ≥0.09). We observed no associations between SNPs or haplotypes and DAS28 scores at baseline or at year 1
(P ≥0.10).
Conclusion: CRP genotype and haplotype were only marginally associated with serum CRP levels and had no
association with the DAS28 score. This study shows that DAS28, the core parameter for inflammatory activity in RA,
can be used for clinical decision-making without adjustment for CRP gene variants.
Trial registration: The OPERA study is registered at Clinicaltrials.gov (NCT00660647). The CIMESTRA study is not
listed in a clinical trials registry, because patients were included between October 1999 and October 2002.* Correspondence: c.ammitz@gmail.com
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8000 Aarhus C, Denmark
2Department of Medicine, Randers Regional Hospital, Skovlyvej 1, 8930
Randers, Denmark
Full list of author information is available at the end of the article
© 2014 Ammitzbøll et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public
Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this
article, unless otherwise stated.
Ammitzbøll et al. Arthritis Research & Therapy 2014, 16:475 Page 2 of 8
http://arthritis-research.com/content/16/5/475Introduction
C-reactive protein (CRP) was discovered in 1930 by Tillet
and Francis [1]. They realized that serum from febrile pa-
tients formed a precipitate when mixed with a Strepto-
coccus pneumoniae capsule component due to binding
of CRP to phosphorylcholine, a major constituent of
C-polysaccharide. CRP is a highly conserved protein be-
longing to the pentraxin family and is a key component of
the acute-phase response to infection and inflammation.
CRP is in widespread clinical use as a sensitive but non-
specific marker of inflammation; a normal CRP expression
level is below 10 mg/L in healthy individuals [2]. CRP
levels may increase up to 1,000-fold following an acute-
phase stimulus, owing to increased hepatic transcription,
mainly in response to the proinflammatory cytokine inter-
leukin 6 [2,3]. Several factors, such as age, sex, smoking
and body mass index, have been shown to influence basal
serum CRP levels in the absence of inflammatory stimuli
[4-6].
CRP is encoded by the CRP gene, which is located on
chromosome 1q23. CRP consists of two exons spanning
2.3 kb (Figure 1). CRP levels are under genetic influence
[7], and several single-nucleotide polymorphisms (SNPs)
in the CRP gene and their haplotypes have been associated
with basal CRP concentrations and the magnitude of the
acute-phase rise in CRP levels in active inflammation
[8-14]. Much of the work in this area has been instigated
by the association found between elevated basal CRP
levels and increased risk for cardiovascular disease [15].A
B
Figure 1 Single-nucleotide polymorphisms and haplotypes in
the CRP gene. (A) Schematic representation of the CRP gene drawn
to scale. Exons are represented as blue boxes. Dots represent the
locations of the seven single-nucleotide polymorphisms investigated in
this study. Zigzag lines indicate truncation of nucleotides. (B) Haplotypes
and names are in agreement with those used in previous publications
[16,17]. The nucleotides are stated according to the plus strand. The
frequencies of haplotypes are given as percentages.Rhodes et al. reported a 3.5-fold change in expected
serum CRP levels between carriers of two common CRP
haplotypes in two cross-sectional cohorts of patients with
chronic rheumatoid arthritis (RA) when the erythrocyte
sedimentation rate was used to adjust for the varying de-
gree of inflammatory disease activity [18]. Rhodes and col-
leagues speculated that genetic effects of this magnitude
on CRP levels could result in suboptimal treatment due to
the use of CRP-based (Disease Activity Score in 28 joints
(DAS28)) treatment algorithms; for example, patients with
low CRP production might receive inappropriate assur-
ance or suboptimal treatment [16,18]. In contrast, Plant et
al. recently published an analysis of a cohort of patients
with chronic RA in whom they found no sign of an asso-
ciation between CRP variants and CRP, DAS28 or change
in DAS28 after treatment with an anti–tumor necrosis
factor inhibitor over a 6-month period [17]. In both stud-
ies, the researchers investigated patients with chronic RA
who were being treated with a wide range of disease-
modifying antirheumatic drugs (DMARDs), which could
explain the diverging results. A cohort consisting of
patients with early RA (ERA) who were DMARD- and
steroid-naïve was unique to investigate, as they presented
with the acute phase of chronic inflammation unaffected
by the modifications of DMARD and steroid treatment.
Our aim was to investigate the importance of seven
CRP SNPs in 315 patients with ERA who were DMARD-
and steroid-naïve by determination of their genotype and
haplotype associations with CRP and DAS28 score at
baseline and after 1 year of treatment. The patients were
derived from two previously conducted national random-
ized controlled trials.
Methods
Study participants
The study was based on two cohorts. Cohort 1 was
derived from the OPERA study (ClinicalTrials.gov ID:
NCT00660647) [19]. It was composed of 188 patients with
ERA who were DMARD- and steroid-naïve were included
in a randomized, double-blind, placebo-controlled trial of
methotrexate, intra-articular (i.a.) glucocorticoids plus ei-
ther adalimumab or placebo. Cohort 2 was composed of
the patients in the CIMESTRA trial [20-22], which was a
randomized, double-blind, placebo-controlled, investigator-
initiated trial on 160 patients with ERA who were
DMARD- and steroid-naïve and being treated with me-
thotrexate and i.a. glucocorticoids plus either cyclosporine
or placebo. DNA was available for all patients in cohort 1
and for 135 patients in cohort 2, so we had a total of 315
patients. The two cohorts had similar inclusion criteria.
All patients fulfilled the 1987 American College of Rheu-
matology criteria for RA [23], had a disease duration of
less than 6 months and were DMARD- and steroid-naïve.
They had clinically active disease with a DAS28 score >3.2
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treatment strategy of both studies was to achieve early
and sustained synovitis suppression by aggressive use of i.
a. glucocorticoids and DMARDs as a “treat-to-target”
strategy [24]. The placebo groups of both studies were
treated similarly (methotrexate and i.a. glucocorticoids),
although the escalation rate of methotrexate and the type
of glucocorticoid used (triamcinolone in OPERA and
betamethasone in CIMESTRA) differed. Oral glucocor-
ticoids were not allowed. There were only minor differ-
ences in patient characteristics between the two cohorts
(Table 1). The median age of the included patients was
54 years; 66% were women; median disease duration was
just under 3 months; and 70% were rheumatoid factor–
positive. Serum CRP was measured at baseline for all pa-
tients and at year 1 for 170 patients in cohort 1 and 122
patients in cohort 2.
Ethics
All patients gave their written informed consent, and
ethical approval was obtained from the local ethics
committee (De Videnskabsetiske Komitéer for Region
Midtjylland, M-20110150).
Single-nucleotide polymorphism selection and
genotyping
The seven CRP SNPs studied (rs11265257, rs1130864,
rs1205, rs1800947, rs2808632, rs3093077 and rs876538)
were selected on the basis of previous publications in
rheumatic diseases [16,18,25] (Figure 1). The nucleotides
are stated according to the plus strand. Genotyping was
analyzed using the TaqMan OpenArray system from
Applied Biosystems (Foster City, CA, USA). We typedTable 1 Patient characteristics of the two cohortsa
Baseline Cohort 1 (N =180)
Age, yr 55 (27 to 78
Female sex 66%
Disease duration, days 84 (42 to 16
Rheumatoid factor–positive, % 72%
Anti-CCP-positive, % 65%
Tender joint count 11 (3 to 26
Swollen joint count 8 (2 to 23
Patient global assessment, mm 67 (13 to 98
CRP, mg/L 14 (1 to 132
DAS28 score 5.6 (3.8 to 7.7
HAQ 1.1 (0.1 to 2.5
Year 1
CRP, mg/L 2 (0.5 to 19
DAS28 score 2.0 (1.7 to 4.3
aValues are medians with 5% to 95% percentile values in parentheses, unless other
28 joints; HAQ, Health Assessment Questionnaire. Fisher’s exact test and the Mann–one SNP with a custom-designed genotyping assay and six
SNPs with a predesigned assay from Applied Biosystems
(see Additional file 1: Table S1 for assay information). We
have previously described this method in more detail [26].
OpenArray plates were manufactured by Applied Biosys-
tems. A nontemplate control was introduced within each
set of assays. TaqMan OpenArray Master Mix was used
according to the manufacturer’s protocol. Samples were
loaded into OpenArray plates using the OpenArray NT
Autoloader and cycled using the GeneAmp PCR System
9700 thermal cycler with PCR conditions set according to
the manufacturer’s protocol. The arrays were read using
the OpenArray NT Imager, and the allele calls and scatter-
plots were generated with the genotyping software asso-
ciated with the OpenArray system.
C-reactive protein measurements
CRP levels (range, 8 to 160 mg/L) in serum were mea-
sured using QuikRead go CRP (Orion Diagnostica, Espoo,
Finland) [27] in cohort 1, and CRP values below 10 mg/L
were reanalyzed with a high-sensitivity CRP assay to im-
prove the sensitivity. CRP was measured using standard
laboratory methods in each of the participating centers in
cohort 2 [28].
Statistical analysis
CRP concentrations in serum were log-normally dis-
tributed and, therefore, log-transformed before analysis.
The genotype distribution was tested for deviation from
Hardy-Weinberg equilibrium using Haploview software
[29], which was also used for population-based haplotype
analysis. Analysis of variance based on multiple linear re-
gression models was used to investigate the associationCohort 2 (N =135) P-value
) 52 (26 to 71) 0.11
65% 0.91
2) 98 (48 to 175) <0.001
68% 0.54
60% 0.41
) 9 (2 to 22) 0.07
) 8 (2 to 20) 0.41
) 50 (10 to 91) <0.001
) 20 (2 to 105) 0.04
) 5.3 (3.2 to 7.1) 0.02
) 1.0 (0 to 2.3) 0.02
) 7 (0.7 to 33) <0.001
) 2.0 (1.3 to 5.1) 0.13
wise stated. CCP, Cyclic citrullinated peptide; DAS28, Disease Activity Score in
Whitney rank-sum test were used when appropriate.
Ammitzbøll et al. Arthritis Research & Therapy 2014, 16:475 Page 4 of 8
http://arthritis-research.com/content/16/5/475between CRP and genotypes with age, sex and treatment
as covariates. The genotype was modeled as an additive
allelic effect. The two cohorts were combined in the ana-
lysis of the genotype and haplotype effects.
Tests of haplotype association with protein levels were
performed by using haplo.stats in the R statistical software
package, version 1.6.3 [30]. For all analyses, we assumed
additive haplotype effects and Gaussian distribution of
traits and phenotypes. First, the haplo.score was used to
study associations between the combined haplotypes and
CRP levels by calculating global P-values. Next, the haplo.
glm function was used to account for ambiguity of ha-
plotype estimation and multiple comparisons so that we
could estimate the effect of each haplotype compared to
the most frequent haplotype (H3) by linear regression
analysis. Age, sex and treatment were added as covariates
in all haplotype analyses. In contrast to assigning the most
likely haplotype phase resolution to each sample, the
haplo.glm function estimates a generalized linear model
by incorporating the haplotype phase uncertainty by infer-
ring a probability matrix of haplotype likelihoods for each
individual by use of the expectation-maximization haplo-
type inference algorithm.
Results with P-values below 0.05 were considered sig-
nificant, and 95% confidence intervals (CI) are used
throughout. Data are presented as medians (5th to 95th
percentile ranges), unless otherwise stated. Fisher’s exact
test, the Mann–Whitney rank-sum test and Student’s
t-test were used to test population differences. Stata 12.1
software (StataCorp, College Station, TX, USA) was used
for analysis.
Results
No difference was observed between the two cohorts con-
cerning age, sex, anti–cyclic citrullinated peptide or im-
munoglobulin M rheumatoid factor positivity (Table 1).
There were significant differences in serum CRP levels be-
tween the two cohorts, with cohort 1 having the lowest
levels. At baseline, cohort 1 had a median CRP level of
14 mg/L compared to 20 mg/L in cohort 2 (P = 0.04); at
year 1, the median CRP level in cohort 1 was 2 mg/L com-
pared to 7 mg/L in cohort 2 (P <0.001). Seventeen percent
of the CRP measurements were >10 mg/L in cohort 1
compared to 40% in cohort 2 at year 1.
There were no differences between the two cohorts in
the genotype frequency of the seven SNPs (all P ≥0.70).
The minor allele frequency values (cohort 1/cohort 2)
were rs11265257 (0.39/0.40), rs1130864 (0.31/0.30), rs1205
(0.32/0.31), rs1800947 (0.06/0.06), rs2808632 (0.31/0.33),
rs3093077 (0.05/0.04) and rs876538 (0.22/0.24). These
SNPs were genotyped in 315 samples. The genotyping
success rate was >99%, and no deviation from the
Hardy-Weinberg equilibrium was observed (all P ≥0.163)
(Additional file 2: Table S2).Table 2 shows the association between SNPs and CRP
as well as DAS28 levels, with sex, age and treatment as co-
variates. rs1205 (C > T) was associated with CRP levels at
baseline in an allele dose-dependent way, with the minor
T allele associated with lower values (P = 0.03). The re-
gression analysis revealed a reduction to 50% CI (29 to 84)
in baseline CRP levels for individuals homozygous for the
minor T allele compared to the homozygosity of the major
allele, and to 55% CI (33 to 94) compared to heterozygous
for the minor T allele. Figure 2 gives a graphical presenta-
tion of the findings and demonstrates the large deviation
in CRP in patients with ERA at diagnosis, with more than
a 100-fold difference in serum CRP levels. No other SNPs
were associated with baseline serum CRP levels, and none
were significant at year 1, including rs1205 (all P ≥0.14).
We found no genotype effect of the seven SNPs on
DAS28 levels at either baseline or year 1 (all P ≥0.10)
(Table 2).
Five haplotypes were constructed with frequencies be-
tween 6% and 32%, encompassing >99% of the cohort
(Table 3 and Figure 1). These haplotypes are in agreement
with the haplotypes previously published by Rhodes et al.
[18] and Plant et al. [17]. We have named our haplotypes
H1 to H5, similarly to Plant and colleagues and the
authors of a recent review [16]. Rhodes and colleagues
interchanged the haplotypes H4 and H5 [18]. “Haplo.
score” revealed a significant global P-value of 0.04 between
the combined haplotypes, and CRP levels at baseline and
borderline were significant at year 1 (P = 0.06). There
was no association between the combined haplotypes
and DAS28 scores at either baseline (P = 0.10) or year 1
(P = 0.25), as judged by the global P-values. The results of
the linear regression analysis (“haplo.glm”) are given in
Table 3 as effects expressed in percentages compared to
the reference haplotype H3. The H2 haplotype, cha-
racterized by the T allele of rs1205, was significantly
associated with a reduction in CRP levels to 74% (55 to
99) (P = 0.043) at baseline, whereas no effect was observed
at year 1. H5, which also includes the T allele of rs1205,
was borderline significant at baseline with a reduction of
64% (40 to 103) (P = 0.07). No significant associations
were seen between any of the other haplotypes and CRP
levels at either baseline or year 1 (Table 3). No haplotype
was associated with the DAS28 score at either baseline or
year 1 (all P ≥0.23).
Discussion
To the best of our knowledge, this study is the first in
which the associations between CRP SNPs, serum CRP
levels and DAS28 scores have been investigated in a co-
hort of patients with inflammatory active early RA who
were DMARD- and steroid-naïve. We found an asso-
ciation between rs1205 and serum CRP levels at baseline
that translated into a reduction of 50% in CRP levels in
Table 2 Genotype effect on serum C-reactive protein level and Disease Activity Score in 28 joints at baseline and
year 1a
Baseline CRP Year 1 CRP Baseline DAS28 Year 1 DAS28
SNP β P-value β P-value β P-value β P-value
rs11265257 −0.14 0.19 −0.01 0.91 −0.09 0.31 −0.06 0.49
rs1130864 0.15 0.21 0.03 0.78 0.16 0.10 0.14 0.12
rs1205 −0.26 0.03 −0.09 0.38 −0.08 0.39 −0.09 0.32
rs1800947 −0.34 0.14 −0.12 0.57 0.02 0.91 0.23 0.21
rs2808632 0.18 0.15 −0.04 0.73 −0.04 0.71 −0.08 0.40
rs3093077 −0.10 0.69 0.30 0.16 −0.26 0.21 −0.02 0.90
rs876538 0.15 0.28 −0.05 0.66 0.02 0.86 −0.02 0.87
aLinear regression analysis with age, sex and treatment as covariates. CRP, C-reactive protein; DAS28, Disease Activity Score in 28 joints; SNP, Single-nucleotide
polymorphism.
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effects were observed at year 1. We found genetic va-
riants in the CRP gene to be of questionable clinical sig-
nificance in RA, as there was no association with DAS28
levels. Thus, we propose that DAS28 still can be used2
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Figure 2 Serum C-reactive protein concentrations divided by
rs1205 genotype at baseline. Serum C-reactive protein (CRP)
concentrations of 313 patients with early rheumatoid arthritis at their
time of diagnosis according to rs1205 genotype. Circles indicate
individual serum CRP concentrations. The boxes indicate geometric
means and 95% CIs calculated from linear regression analysis corrected
for age, sex and treatment. *P <0.05.for clinical decision-making without adjustment for CRP
gene variants.
The minor allele of rs1205 (C > T) was associated with
decreased CRP levels at baseline. Homozygosity of the
minor allele (TT genotype) was associated with a 50%
reduction in CRP from 16.7 to 8.4 mg/L (Figure 1),
which is in accordance with a similar 40% reduction de-
scribed by Rhodes et al. [18]; however, Plant et al. did
not find such an association (P = 0.17) [17]. Multiple
studies with different patient populations have shown
similar findings [12,13,25,31-33]. The absolute differ-
ences in two population-based studies of basal CRP were
minute, with a difference in CRP of less than 1 mg/L
between the CC and TT genotypes [12,32], but highly
significant because of the high numbers of individuals
included (N = 7,983 [12] and N = 3,107 [32]). Similar
findings with a difference of about 30% following acute
coronary ischemia have been described [31].
We did not find an association at year 1 between
rs1205 and serum CRP levels, for which there are several
possible explanations. CRP is the most commonly used
biochemical variable to monitor disease activity, and, as
both of the cohorts we included were derived from ran-
domized controlled trials focused on aggressive, esca-
lating treatment and tight disease control [19,20], this
would bias the study by applying more aggressive treat-
ment to the common variants of rs1205 (with higher
CRP levels), thereby masking the genetic effect. A second
explanation is that our study was underpowered to detect
the 0.2 mg/L difference in CRP found at year 1 between
the CC (4.6 mg/L) and TT (4.4 mg/L) genotypes.
We did not find a genotype or haplotype association
with the DAS28 score at baseline, which is not surpris-
ing when one looks closely at the composition of the
DAS28 equation [34]. The difference in CRP levels at
baseline between the rs1205 CC (16.7 mg/L) and TT
(8.4 mg/L) genotypes translates into a reduction in the
DAS28 score of 0.23, which represents only 4% of the
mean DAS28 score of 5.4 in the combined cohort. A
Table 3 CRP haplotype build, frequency and effect on serum C-reactive protein and Disease Activity Score in 28 joints
at baseline and year 1a
Haplotype Frequency Baseline CRP, effect (CI) Year 1 CRP, effect (CI) Baseline DAS28, effect (CI) Year 1 DAS28, effect (CI)
H1 (CACT) 30.5% 96% (73 to 126) 99% (77 to 126) 102% (98 to 107) 105% (97 to 113)
H2 (TGCT) 25.7% 74% (55 to 99) 91% (70 to 118) 99% (94 to 103) 97% (89 to 106)
H3 (CGCG) 31.4% 100% 100% 100% 100%
H4 (CGCT) 6.2% 66% (41 to 107) 121% (80 to 184) 95% (88 to 103) 102% (89 to 116)
H5 (TGGT) 5.5% 64% (40 to 103) 86% (56 to 134) 101% (93 to 108) 110% (95 to 124)
Haplotype defining SNPs = (rs1205, rs1130864, rs1800947, rs2808632). The effects of each haplotype were given relative to the most frequent haplotype, which
was used as reference. CRP, C-reactive protein; DAS28, Disease Activity Score in 28 joints; SNP, Single-nucleotide polymorphism.
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should be included to detect such a change, with the es-
timated standard deviations of 1.12, a power of 0.80 and
a significance level of 0.05. Plant et al. similarly observed
no haplotype effects on DAS28 score or change in
DAS28 score after 6 months of treatment with anti–
tumor necrosis factor inhibitor therapy in 442 chronic
RA patients [17]. Rhodes et al. reported a 3.5-fold
change in expected CRP levels between the H1 and H5
(named H4 in the Rhodes article) haplotypes when the
erythrocyte sedimentation rate was used to adjust for
the varying degree of inflammatory disease activity, but
their study lacked sufficient clinical data to report
DAS28 scores [16]. They further speculated that genetic
effects of this magnitude on CRP levels may result in
suboptimal treatment because of the widespread use of
CRP-based treatment algorithms (DAS28); for example,
low CRP producers may receive inappropriate assurance
or suboptimal treatment [18]. The absence of an asso-
ciation between geno- and haplotypes with DAS28 score
in the present study accords with data previously re-
ported by Plant et al. [17] and hence do not support
concerns raised by Rhodes et al. [16,18] that genetically
determined variability of CRP levels in serum may in-
fluence the assessment of disease activity in ERA or
chronic RA.
The present study differs from two previously published
studies regarding RA [17,18]. The patients had a median
disease duration of 12 years in the Plant et al. study [17].
Although disease duration was not provided in the Rhodes
et al. report [18], we assume a similar duration because
their patients’ median age was 62 years. This is in contrast
to our study, in which patients had treatment-naïve ERA
at the time of inclusion (median disease duration of
3 months and median age of 54 years); that is, at the time
of inclusion, our patients represented a fairly homoge-
neous cohort of untreated patients with ERA. It is unique
to investigate untreated patients with ERA, as the rise in
CRP associated with the appearance of RA is unaffected
by treatment, rendering the analysis of the genetic effects
on CRP levels more robust. Our study had fewer patients
included than the two previous studies [17,18], but this iscounterbalanced by the use of randomized controlled trial
cohorts, short disease duration and the focus on untreated
patients with ERA.
In this study, we focused on the hypothesis that gene-
tically determined low serum levels of CRP may lead to
underestimation of RA disease activity. Of note, how-
ever, high CRP production may also be harmful. First,
CRP participates in the activation and regulation of all
three pathways of the complement system [35], which is
activated in RA [36]. Second, increased serum CRP con-
centration at baseline is an important predictor of subse-
quent death due to cardiovascular disease in patients
with new-onset inflammatory polyarthritis, and it is
independent of other indicators of disease severity [37].
Finally, several clinical studies have shown that high
levels of CRP are associated with a more aggressive dis-
ease course and increased joint destruction [38].Conclusion
The CRP genotype and haplotype were only marginally
associated with serum CRP levels and were not asso-
ciated with DAS28 scores. Thus, this study shows that
DAS28, which is the core parameter for inflammatory
activity in RA, can be used for clinical decision-making
without adjustment for CRP gene variants.Additional files
Additional file 1: Table S1. Assay information for the seven SNPs
genotyped in 315 early RA patients. This table list the assay IDs, primers
and probes used to analyze the seven CRP SNPs.
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